Insulin Patch Pumps Market Size, Share & Trends Analysis Report By Delivery Mode (Basal, Bolus, Basal & Bolus), By Product Type (Disposable, Reusable), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global insulin patch pumps market size was valued at USD 836.14 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 10.73% from 2022 to 2030. The high growth can primarily be attributed to factors such as rising prevalence of diabetes, technological advancements, and increasing awareness regarding advanced patch pumps. For instance, according to the International Diabetes Federation, approximately 536,600 adults were living with diabetes in 2021 and this number is expected to reach 783,700 by 2045. People with type 1 diabetes prefer insulin patch pumps as they do not need to carry an insulin infusion set. Owing to higher convenience, the patch pumps are preferred by older and working people.

Insulin patch pumps are efficient devices as they are smaller than conventional insulin pumps, more discrete, and easier to use. Moreover, these pumps are more affordable compared to conventional ones, which eventually generates more demand. Patch pumps are attached to the skin using an adhesive layer and due to the advanced technology, they require minimum monitoring. These pumps are usually integrated with blood glucose or continuous glucose monitoring systems. Technological advancements and the use of artificial intelligence in this field are expected to play a significant role in replacing traditional vial-syringe combinations. Increasing frequency of product launches along with collaborations between major market players and technology developers is also expected to boost the market competition. For instance, Tandem Diabetes Care is developing t:sport insulin pump, which will be half the size of its t:slim X2. The availability of custom-made patch pumps is expected to increase the popularity of these devices during the forecast period. The discrete nature of the devices is one of the major factors increasing their adoption in the younger population.

The increasing prevalence of diabetes worldwide is expected to present lucrative opportunities for advanced diabetes management devices, including patch pumps. According to the International Diabetes Federation, the global diabetic population is expected to reach 783,700 by 2045, which includes a significant number of older people. The same source states that about 6 million Americans use insulin to help control their diabetes. The COVID-19 pandemic has raised the risk of infection, serious consequences (such as kidney disease and ischemic heart disease), and mortality in populations with diabetes. However, one in five patients had difficulty finding blood glucose monitoring devices, and 20% had difficulty getting their insulin pumps filled on time, primarily because of financial limitations. Furthermore, there was a disruption in the supply chain due to the closure of manufacturing sites, shipping delays or shutdowns, and trade limitations or export bans on life-saving drugs such as insulin.

Delivery Mode Insights

The basal and bolus segment dominated the market in 2021 with a revenue share of over 55.0% and is expected to maintain its position over the forecast period owing to the advanced features and the availability of a wide variety of products. Basal and bolus therapy helps normalize blood sugar levels without increasing the risk of hypoglycemia. Moreover, basal and bolus therapy includes an injection after each meal, which emulates the activity of the healthy pancreas. In addition, these therapies are used by both type 1 and type 2 diabetes patients, hence dominating the market. Based on the delivery mode, the market is segmented into basal, bolus, and basal and bolus.

The basal segment captured a significant share in 2021 and is anticipated to grow at a rapid pace. This high growth rate can primarily be attributed to increased adoption among type 1 diabetes patients. Basal insulin pump therapy acts on a slow release mechanism, which is important for managing type 1 diabetes. All types of basal insulins are long-acting and mimic the natural function of the pancreas.

Product Type Insights

The reusable insulin patch pump segment dominated the market in 2021 with a revenue share of over 60.0% and is expected to maintain its dominance over the forecast period. This can be attributed to the increased adoption of these pumps and high frequency of product launches. These devices are highly flexible and capable of delivering complex regimens of insulin to patients. Based on product type, the market is segmented into disposable and reusable patch pumps.

Disposable insulin pumps are mechanical pumps and are also called simplified devices. The majority of these types of patch pumps have some disposable parts, while others are completely disposable. Currently, V-Go by Valeritas and PAQ by CeQur dominate the market as they have a strong presence in the U.S. as well as Europe. Such patch pumps provide consistent and adjustable insulin delivery, with fewer insulin injections.

Distribution Channel Insights

The hospitals segment dominated the market in 2021 with a revenue share of over 50.0% owing to factors such as increasing number of specialty hospital pharmacies and the expansion of the integrated delivery network. Most first-time patch pump users tend to buy these from hospital pharmacies. Considering the recent shift in trend from traditional to automated insulin delivery solutions, the hospital pharmacy segment is expected to witness significant growth over the forecast period. By distribution channel, the market is segmented into hospitals, retail pharmacies, private clinics, online pharmacies, and others.

The online pharmacies segment is expected to exhibit the fastest CAGR during the forecast period. The high growth rate of the segment can primarily be attributed to factors such as rising awareness regarding online pharmacies, lower costs, convenience, and increase in awareness campaigns by online pharmacies. However, purchasing insulin patches through online pharmacies may involve risks such as wrong product delivery and improper usage.

Regional Insights

North America dominated the market with a revenue share of over 35.0% in 2021 owing to the availability of major brands of insulin patch pumps. Moreover, increasing healthcare expenditure and rising frequency of FDA approvals are aiding market growth in the region. For instance, in 2019, EoFlow, a South Korean Company, received FDA approval for its newly designed patch pump-EOPatch-in the U.S. Moreover, according to the International Diabetes Federation, the diabetic-related healthcare expenditure per person in the U.S. was about USD 8,468 in 2011, which increased to USD 11,779 in 2021, and is further expected to increase to USD 12,184 by 2045.

Asia Pacific is expected to grow at the fastest rate over the forecast period due to factors such as the rapidly growing diabetic population and increasing awareness regarding advanced diabetes management solutions in the region. According to the International Diabetes Federation, India and China account for the largest number of diabetes patients in the world. Most of the countries in this region are developing countries and the increase in obesity cases and growing socio-economic changes have fueled the occurrence of type I and type II diabetes. In addition, increasing product launches and technological advancements in the field of insulin patch pumps are expected to aid regional growth.

Key Companies & Market Share Insights

Key market players are focused on adopting new technologies, introducing advanced products, taking advantage of important cooperation activities, and exploring mergers & acquisitions in order to offer better services to their customers and strengthen their presence in the market. For instance, in November 2020, Terumo Corporation, a leading manufacturer of medical technology, received CE Mark for its MEDISAFE WITHTM insulin pump system. Some prominent players in the global insulin patch pumps market include:

• Medtronic plc

•  F. Hoffmann-La Roche Ltd.

• Insulet Corporation

• CeQur

• Terumo

• Tandem Diabetes Care

• Medtrum

• Debiotech

Insulin Patch Pumps Market Report Scope

Global Insulin Patch Pumps Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global insulin patch pumps market report on the basis of delivery mode, product type, distribution channel, and region:

• Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)

  • Basal

  • Bolus

  • Basal & Bolus

• Product Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Disposable

  • Reusable

• Distribution Channel Outlook (Revenue USD Million, 2018 - 2030)

  • Hospitals

  • Retail Pharmacies

  • Private Clinics

  • Online Pharmacies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Czech Republic

    • Russia

    • Poland

    • Turkey

    • Switzerland

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Vietnam

    • Philippines

    • Malaysia

    • Indonesia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

    • Chile

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Oman

    • Egypt